Seizures and memory impairment induced by patient‐derived anti‐N‐methyl‐D‐aspartate receptor antibodies in mice are attenuated by anakinra, an interleukin‐1 receptor antagonist
Autor: | Anastasia Zekeridou, Chandana Devi Kattala, Scott K. Dessain, Howard S. Fox, Olga Taraschenko, Fetweh H. Al-Saleem, George P. Casale, Fnu Farukhuddin, Sean J. Pittock, Raymond Dingledine, Gregory Willcockson, Ember Eldridge |
---|---|
Rok vydání: | 2021 |
Předmět: |
Male
0301 basic medicine medicine.drug_class Pharmacology Hippocampus Receptors N-Methyl-D-Aspartate Article Mice 03 medical and health sciences 0302 clinical medicine Seizures medicine Animals Humans Autoantibodies Anti-NMDA receptor encephalitis Anakinra Glial fibrillary acidic protein biology business.industry Receptors Interleukin-1 Interleukin Electroencephalography Amnesia Anterograde Receptor antagonist medicine.disease Mice Inbred C57BL Interleukin 1 Receptor Antagonist Protein 030104 developmental biology Interleukin 1 receptor antagonist Neurology Astrocytes biology.protein NMDA receptor Anticonvulsants Microglia Neurology (clinical) business Open Field Test 030217 neurology & neurosurgery Encephalitis medicine.drug |
Zdroj: | Epilepsia |
ISSN: | 1528-1167 0013-9580 |
DOI: | 10.1111/epi.16838 |
Popis: | Objective Neuroinflammation associated with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis may facilitate seizures. We previously showed that intraventricular administration of cerebrospinal fluid from patients with anti-NMDAR encephalitis to mice precipitates seizures, thereby confirming that antibodies are directly pathogenic. To determine whether interleukin (IL)-1-mediated inflammation exacerbates autoimmune seizures, we asked whether blocking the effects of IL-1 by anakinra, a selective IL-1 receptor antagonist, blunts antibody-induced seizures. Methods We infused C57BL/6 mice intraventricularly with purified serum IgG from patients with anti-NMDAR encephalitis or monoclonal anti-NMDAR IgG; subdural electroencephalogram was continuously recorded. After a 6-day interval, mice received anakinra (25 mg/kg sc, twice daily) or vehicle for 5 days. Following a 4-day washout period, we performed behavioral tests to assess motor function, anxiety, and memory, followed by hippocampus tissue analysis to assess astrocytic (glial fibrillary acidic protein [GFAP]) and microglial (ionized calcium-binding adapter molecule [Iba]-1) activation. Results Of 31 mice infused with purified patient NMDAR-IgG (n = 17) or monoclonal NMDAR-IgG (n = 14), 81% developed seizures. Median baseline daily seizure count during exposure to antibodies was 3.9; most seizures were electrographic. Median duration of seizures during the baseline was 82.5 s. Anakinra administration attenuated daily seizure frequency by 60% (p = .02). Anakinra reduced seizure duration; however, the effect was delayed and became apparent only after the cessation of treatment (p = .04). Anakinra improved novel object recognition in mice with antibody-induced seizures (p = .03) but did not alter other behaviors. Anakinra reduced the expression of GFAP and Iba-1 in the hippocampus of mice with seizures, indicating decreased astrocytic and microglial activation. Significance Our evidence supports a role for IL-1 in the pathogenesis of seizures in anti-NMDAR encephalitis. These data are consistent with therapeutic effects of anakinra in other severe autoimmune and inflammatory seizure syndromes. Targeting inflammation via blocking IL-1 receptor-mediated signaling may be promising for developing novel treatments for refractory autoimmune seizures. |
Databáze: | OpenAIRE |
Externí odkaz: |